Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2009, p. 175-181, Vol. 47, No. 1
0095-1137/09/$08.00+0 doi:10.1128/JCM.01851-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Respiratory Disease Branch, Centers for Disease Control and Prevention, Atlanta, Georgia,1 Infectious Diseases Laboratory, College of Veterinary Medicine, University of Georgia, Athens, Georgia,2 Ameritek USA, Everett, Washington3
Received 24 September 2008/ Returned for modification 29 October 2008/ Accepted 31 October 2008
|
|
|---|
|
|
|---|
C. psittaci is currently grouped into seven avian genotypes (A through F and a newly identified genotype, E/B) and two nonavian genotypes (M56 and WC) (5). Recent reclassification of C. psittaci has resulted in the separation of C. abortus and C. caviae into distinct species, although these species are genetically closely related (2, 22). Identification and genotyping of C. psittaci in avian samples and isolates are currently achieved by serological testing and molecular methods, such as outer membrane protein A (ompA) gene sequencing, restriction fragment length polymorphism (RFLP), and cumbersome real-time PCR assays and microarray analysis (6, 16, 18, 23). For diagnosis in humans, culture is rarely performed because the procedure is labor-intensive and requires specialized laboratory expertise and equipment. Thus, accurate diagnosis is often delayed or missed and may result in improper treatment for patients (3). Diagnosis by molecular techniques, such as real-time PCR, is not readily available in most public health laboratories, forcing them to rely upon insensitive complement fixation or microimmunofluorescence tests for detecting C. psittaci antibodies in suspect cases (14). Since both complement fixation and microimmunofluorescence require acute and convalescent-phase sera, they are retrospective assays considered inadequate for a timely diagnosis. A reliable and rapid assay for detecting and genotyping C. psittaci strains would greatly enhance the diagnostic capability for this agent and facilitate timely treatment.
This study reports the development of a real-time PCR assay followed by high-resolution melt (HRM) analysis using light-upon-extension (LUX) chemistry to specifically detect and genotype C. psittaci. This assay may be useful for epidemiological studies and provide valuable information for designing public health measures during outbreaks. This method may also offer greater insight into the heterogeneity of this species. To our knowledge, this is the first report of an HRM-based real-time PCR assay that simultaneously detects and genotypes this species.
|
|
|---|
C. psittaci culture. C. psittaci reference strains were propagated in Vero cell monolayers grown in 25-cm2 culture flasks in Eagle's minimal essential medium (MEM) supplemented with MEM nonessential amino acids, 2 µM L-glutamine, 20 µM HEPES buffer, 10% fetal calf serum, 20 µg/ml streptomycin, and 25 µg/ml vancomycin. Confluent Vero cell monolayers were inoculated by replacing the growth medium with 1 ml of stock C. psittaci culture diluted 1:10 in MEM containing 1 µg/ml of cycloheximide. The inoculated monolayers were placed at 37°C for 2 h before an additional 4 ml of MEM containing cycloheximide was added to each flask. Cultures were incubated for 7 days at 37°C or until the monolayers demonstrated an approximately 70% cytopathic effect, and the remaining Vero cells were scraped from the flask into the medium. One milliliter of each culture was centrifuged at 20,000 x g for 60 min, and the pellet was resuspended in nuclease-free water (catalog no. P1193; Promega) and used for DNA extraction. The remaining culture was dispensed into aliquots and frozen at –70°C. Titration of cultures was performed as previously described, with 96-well flat-bottom microtiter plates containing Vero cells (21). Frozen C. psittaci cultures of 50-µl quantities at 10-fold dilutions were used to inoculate wells of Vero cells in triplicate. After incubation for 72 h at 37°C in a 5% CO2 atmosphere, the medium was removed and the cells were fixed with methanol and stained with a Chlamydia genus-specific monoclonal antibody (catalog no. 30701; Bio-Rad). Inclusions (inclusion forming units/ml) were counted using an inverted fluorescence microscope.
DNA extraction. DNA from C. psittaci cultures was extracted using a QiaAmp DNA minikit (catalog no. 51304; Qiagen, Inc.) according to the manufacturer's instructions. The DNA was eluted into 200 µl of Qiagen elution buffer and stored at –70°C until tested.
LUX primer design and optimization. Three primer sets targeting the variable regions of the C. psittaci ompA gene were designed. LUX chemistry (Invitrogen) utilizes a 5-carboxyfluorescein (FAM)-labeled primer and an unlabeled primer. All primer sets were designed using the C. psittaci 6BC ompA gene (GenBank accession no. X56980), the 90/105 ompA gene (GenBank accession no. AY762608), and the 7778B15 ompA gene (GenBank accession no. AY762612). All C. psittaci primer sequences and expected amplicon sizes are listed in Table 1. Ppac was designed to amplify all C. psittaci genotypes, while GTpc specifically amplifies C. psittaci genotypes. The Ppac assay demonstrated a 96% efficiency, while GTpc displayed a >99% efficiency, calculated using a standardized dilution series of quantitated DNA of C. psittaci tested in triplicate over 6 logs (200 pg to 2 fg). The average for these data is reported as the square of the coefficient of regression values (efficiency); both assays had a lower limit of detection of 200 fg. A specific C. caviae marker targeting the ompA gene of C. caviae (GenBank accession no. AF269282) was designed using the above-described chemistry with unlabeled C.cav-F (5'-CCGTTGCAGACAGGAATAACA-3') and FAM-labeled C.cav-R (5'-cacaaaGCTAAGAAAGCCGCGTTTG"t"G-3' [the 5' lowercase letters are not part of the primer itself but correspond to a self-quenching, complementary tail; "t" represents the FAM binding location]). The expected amplicon size is 78 bp.
|
View this table: [in a new window] |
TABLE 1. Chlamydia oligonucleotide sequencesa
|
Sequencing. Amplification of the ompA gene from isolate strains (DD34, CP3, CT1, NJ1, Vr-122, and VS-225) and specimens (no. 3, 5, 25, 30, 31, and 83) was performed using previously published primers and newly developed primers ompA-F (5'-ACTATGTGGGAAGGTGCT-3') and ompA-R (5'-TAGACTTCATTTTGTTGATCTGA-3') (11). The PCR mixture was prepared using a SuperMix-UDG platinum quantitative PCR kit (catalog no. 11730-025; Invitrogen) containing the following components per reaction mixture: 5 µl of 10x PCR master mix-MgCl2, 1.5 µl 50 mM MgCl2, final concentrations of 100 nM each of the forward and reverse primers, 0.5 µl of platinum Taq polymerase (5 U/µl), 1 µl of 10 µM PCR nucleotide mixture (catalog no. C1141; Promega), 5 ng of a template, and nuclease-free water (catalog no. P1193; Promega) added to give a final volume of 50 µl. A DNA engine dyad peltier thermocycler (catalog no. PTC-0220G; Bio-Rad) was used for amplification under the following cycling conditions: 1 cycle at 95°C for 2 min, followed by 50 cycles at 95°C for 1 min, 59°C for 1 min, and 72°C for 2 min. Samples were then purified using a QIAquick gel extraction kit (catalog no. 28706; Qiagen) after separation on a 1% agarose gel. Sequencing was performed with an ABI 3130XL instrument (catalog no. 3130XL; Applied Biosystems, Inc.) under standard conditions for an 80-cm capillary. Consensus sequences were generated using DNAstar Lasergene SeqMan Pro software and aligned with published ompA gene sequences for each genotype by using ClustalW software. The GenBank accession numbers used for alignment are as follows: AY762608, AY762609, AF269261, AY762610, AY762611, AY762612, and AY762613.
|
|
|---|
|
View this table: [in a new window] |
TABLE 2. Specificity panela
|
![]() View larger version (15K): [in a new window] |
FIG. 1. HRM analysis. Real-time PCR with HRM was performed in triplicate on all reference strains. HRM is shown in the normalization graph function. (a) Ppac. All C. psittaci genotypes and C. abortus melt together, while C. caviae is distinct. (b) GTpc. All C. psittaci genotypes are clearly distinguished from each other, with the exception of genotypes D and F. (c) GT-F. Genotype F is clearly separated from all other C. psittaci genotypes via positive/negative amplification.
|
Specimen testing. One hundred sixty-nine specimens obtained from birds and companion mammals were screened along with reference strains. Of these archived nucleic acid preparations, 107 (63.3%) were positive for chlamydial DNA, 98 (91.6%) were positive for C. psittaci, and 9 (8.4%) were positive for C. caviae. Of the positive C. psittaci samples, 70 (71.4%) were genotype A, 3 (3.1%) were genotype B, 4 (4.1%) were genotype E, and 21 (21.4%) were positive for C. psittaci (positive amplification for both Ppac and GTpc markers) but could not be typed using this assay, due to inconclusive melt curve data (Table 3). The remaining specimens were negative. All C. caviae strains were obtained from guinea pig specimens, as expected.
|
View this table: [in a new window] |
TABLE 3. Real-time PCR and HRM genotyping results for avian and mammalian specimensa
|
![]() View larger version (38K): [in a new window] |
FIG. 2. Sequence data. (a) Sequence alignment of Ppac amplicons. (b) Sequence alignment of GTpc amplicons. * indicates no consensus sequence; a dash (-) indicates identical sequences. Each genotype (**) is represented by reference strains and, where applicable, specimen sequences. Genotype A includes DD34 and specimens 25 and 83, genotype B includes CP3 and specimens 30 and 31, genotype C includes CT1, genotype D includes NJ1, genotype E includes Vr122 and specimens 3 and 5, and genotype F includes VS225 only. Underscored and bold portions of the sequences are primer binding locations. Genotype E/B is excluded due to the unavailability of the strain.
|
|
|
|---|
The current study reports the development and implementation of a novel diagnostic assay that is capable of rapidly genotyping C. psittaci. A three-marker panel (Ppac, GTpc, and GT-F), with the use of standard cycling conditions followed by a HRM, is able to reliably differentiate genotypes A through F and detect the closely related C. abortus and C. caviae species (2, 22). The Ppac signature sequence serves as a pan marker, able to amplify all C. psittaci genotypes as well as C. caviae and C. abortus, while GTpc separates C. caviae and all C. psittaci genotypes except D/F. The GT-F marker is used to specifically amplify genotype F, thus providing a comprehensive algorithm for identifying and typing these agents. All three markers also demonstrate specificity for their respective targets and sensitivity to 200 fg with C. psittaci reference strain DNA. Further, this assay has been successfully used on clinical specimens and displays 100% concordance with sequence data generated from both reference isolates and clinical extracts. Numerous avian specimens screened for this study were positive for C. psittaci. Genotype A was the most frequently identified genotype, present in 71.4% of the C. psittaci-positive specimens that could be typed. Reportedly, this type is commonly identified in chlamydia-positive psittacine birds, such as parrots, cockatoos, and cockatiels, and is consistent with our findings (9). Both the B and the E genotypes were rarely present, accounting for only 7.2% of specimens. Historically, these genotypes have most commonly been identified in pigeons and doves, again consistent with our data (9). Notably, genotypes C, D, and F were not found in any of the specimens tested, supporting the claim by others that the vast majority of naturally occurring genotypes belong to the ABE cluster (16). C. caviae was detected only in guinea pig specimens (Table 3), where it is known to exist. No specimens tested positive for C. abortus, an agent typically found in mammals, although a few psittacine infections have been reported (2, 15). Neither C. caviae nor C. abortus is considered a classic respiratory pathogen and would not likely be present in respiratory samples being tested for C. psittaci in humans (2). However, if Ppac yields a positive amplification curve while GTpc is negative, C. abortus should be considered and ompA sequencing should be performed for verification. Collectively, the experimental data underscore the utility of this assay.
The reliability of HRM analysis is dependent upon both sufficient quantity and sufficient quality of the starting template. As such, specimens with amplification curves that are not sigmoidal or have threshold cycle values of 40 or above should be interpreted with care due to the possibility of inaccurate melt curve data. If possible, these samples should be concentrated and retested for verification. When threshold cycle values of <40 are achieved, the HRM data are remarkably consistent, reproducible, and reliable, as evidenced by the virtually identical melt curves generated in each of the triplicate wells assayed on numerous occasions and verified by subsequent sequence analysis. The quality and amount of template are inherent limitations in any real-time PCR assay but are especially critical when HRM analysis is performed. These limitations may account for the 21.4% of the specimens that were unable to be definitively genotyped since some older specimens may not have been properly stored after submission (data not shown). Unfortunately, genotype E/B has only recently been described and was unavailable for analysis with this assay (5).
Currently, there exists no rapid and simple procedure which can discriminate among the known genotypes of C. psittaci and have the capability of identifying new strains among the extraordinary genetic heterogeneity found within this species. The current study reports a real-time PCR assay that is able to detect and identify six known C. psittaci genotypes, along with identifying C. caviae and C. abortus. This assay may aid in determining the existence of variants within this species by using the exquisite discriminatory ability of LUX chemistry followed by HRM analysis. The versatility of this assay makes it useful in many applications, such as (i) improving the timely reporting of results, aiding in epidemiological investigations; (ii) possible pathogenicity and transmission studies; (iii) prospective screening of companion birds; (iv) current and retrospective analysis of specimens collected during an outbreak; and (v) a greater characterization of this infectious agent, leading to a better understanding of C. psittaci infection within human and avian populations. This procedure can also contribute to the development of an all-inclusive molecular typing system for this agent.
Published ahead of print on 12 November 2008. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»